| [1] |
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2018, 4(11): 1553-1568.
|
| [2] |
黄健, 王建业, 孔垂泽, 等. 中国泌尿外科和男科疾病诊断治疗指南(2019版)[M]. 北京：科学出版社, 2020, 74.
|
| [3] |
Park S, Reuter V E, Hansel D E. Non‐urothelial carcinomas of the bladder[J]. Histopathology, 2019, 74(1): 97-111.
|
| [4] |
Royce TJ, Lin CC, Gray PJ, et al. Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base[J]. Urol Oncol, 2018, 36(2): 78.e1-78.e12.
|
| [5] |
Abdel-Rahman O. Squamous Cell Carcinoma of the Bladder: A SEER Database Analysis[J]. Clin Genitourin Canc, 2017, 15(3): e463.
|
| [6] |
施文振. 膀胱鳞状细胞癌[D]. 福州,福建医科大学，2006.
|
| [7] |
Ghoneim MA, el-Mekresh MM, el-Baz MA, et al. Radical Cystectomy for Carcinoma of the Bladder[J]. J Urol, 1997, 158(2): 393-399.
|
| [8] |
Pottegrd A, Kristensen KB, Friis S, et al. Urinary tract infections and risk of squamous cell carcinoma bladder cancer: A Danish nationwide case-control study[J]. Int J Cancer, 2020, 146(7): 1930-1936.
|
| [9] |
EL-Bolkainy MN. Topographic Pathology of cancer[M]. Cairo University: The National Cancer Institute, 1998, 59-63.
|
| [10] |
Ishida K, Hsieh MH. Understanding Urogenital Schistosomiasis-Related Bladder Cancer: An Update[J]. Front Med (Lausanne), 2018, 5:223
|
| [11] |
Ploeg M, Aben KK, Hulsbergen-Van d KCA, et al. Clinical Epidemiology of Nonurothelial Bladder Cancer: Analysis of The Netherlands Cancer Registry[J]. J Urol, 2010, 183(3): 915-920.
|
| [12] |
Shaheen A, Isabel AC, Paari M, et al. Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder[J]. World J Urol, 2019, 37(1): 107-114.
|
| [13] |
Mda B, Lfsb C, Grb D, et al. Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder[J]. EJSO, 2021, 47(2): 463-469.
|
| [14] |
Parekh DJ, Reis IM, Castle EP, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet, 2018, 391(10139): 2525-2536.
|
| [15] |
Sathianathen NJ, Kalapara A, Frydenberg M, et al. Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis[J]. J Urol, 2019, 201(4): 715-720.
|
| [16] |
王晓东, 王元林, 石华, 等. 腹腔镜与开放手术方式根治性膀胱切除术治疗膀胱癌的临床研究[J]. 中国内镜杂志, 2016, 22(02): 42-45.
|
| [17] |
曾蜀雄, 张振声, 宋瑞祥, 等. 腹腔镜下与开放式根治性膀胱切除术后早期并发症的对比研究[J].中华泌尿外科杂志, 2015, 36(05): 333-336.
|
| [18] |
Khan MS, Omar K, Ahmed K, et al. Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL)[J]. Eur Urol, 2020 77(1): 110-118.
|
| [19] |
Stensland KD, Zaid H, Broadwin M, et al. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder[J]. Eur Urol Oncol, 2020, 3(4): 509-514.
|
| [20] |
Kastritis E, Dimopoulos MA, Antoniou N, et al. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy[J]. Anticancer Res, 2006, 26(5B): 3865-3869.
|
| [21] |
任昊天, 翟天元, 姚文诚, 等. 膀胱鳞状细胞癌患者临床特征及预后相关因素分析[J].郑州大学学报(医学版), 2021, 56(01): 132-136.
|
| [22] |
Rosiello G, Pecoraro A, Palumbo C, et al. Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study[J]. World J Urol, 2021, 39(3): 813-822.
|
| [23] |
Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology[J]. Cancer, 2017, 123(22): 4346-4355.
|
| [24] |
Dotson A, May A, Davaro F, et al. Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy[J]. Int J Clin Oncol, 2019, 24(6): 706-711.
|
| [25] |
Martin JW, Carballido EM, Ahmed A, et al. Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches[J]. Arab J Urol, 2016, 14(3): 183-191.
|
| [26] |
Khan MS, Thornhill JA, Gaffney E, et al. Keratinising squamous metaplasia of the bladder: natural history and rationalization of management based on review of 54 years experience[J]. Eur Urol, 2002, 42(5): 469-474.
|
| [27] |
Fischer-Valuck BW, Michalski JM, Contreras JA, et al. A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database[J]. Clin Transl Radiat Oncol. 2018, 15: 38-41.
|
| [28] |
Necchi A, Madison R, Raggi D, et al. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder[J]. Eur Urol, 2020 , 77(4): 548-556.
|
| [29] |
Liu Z, Meng Y, Cao Y, et al. Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma[J]. Transl Androl Urol, 2020, 9(2): 428-436.
|
| [30] |
Owyong M, Lotan Y, Kapur P, et al. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder[J]. Urol Oncol, 2019, 37(7): 478-484.
|